From Interfax:

Mustang Bio, Inc. will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on Thursday, January 18, 2024, at 4:30 p.m. EST. To access this event, please RSVP to your B. Riley Securities sales representative. A replay of Mustang’s fireside chat will be available on this link after the meeting.

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies across multiple cancers as well as lentiviral gene therapies for severe combined immunodeficiency. For more information, visit www.mustangbio.com. Contact Mustang Bio, Inc. at (781) 652-4500 or email at [email protected].



Read more: Mustang Bio to Participate in the B. Riley Securities 4th